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Purpose of the study
To investigate the potential of a commonly used botani-
cal supplement, Echinacea purpurea, to interact with the
boosted protease inhibitor darunavir/ritonavir.
Methods
Open-label, fixed-sequence study in 15 HIV-infected
patients receiving antiretroviral therapy including daru-
navir/ritonavir (600/100 mg twice daily) for at least 4
weeks. Echinacea purpurea root extract-containing cap-
sules were added to the antiretroviral treatment (500 mg
every 6 hours) from days 1 to 14. Darunavir concentra-
tions in plasma were determined by using HPLC imme-
diately before and 1, 2, 4, 6, 8, 10 and 12 hours after a
morning dose of darunavir/ritonavir on days 0 (daruna-
vir/ritonavir) and 14 (darunavir/ritonavir + echinacea).
Individual darunavir pharmacokinetic parameters were
calculated by using non-compartmental analysis, and
were compared between days 0 and 14 by using the geo-
metric mean ratio (GMR) and its 95% confidence inter-
val (95% CI).
Results
Median (range) age was 49 (43-67) years, and body mass
index was 24.2 (18.7-27.5) kg/m
2. Echinacea was well
tolerated and all participants completed the study. Rela-
tive to administration of darunavir/ritonavir alone, its
coadministration with Echin a c e ap u r p u r e ar e s u l t e di n
little change in darunavir pharmacokinetic parameters.
Table 1
Conclusions
Coadministration of Echinacea purpurea with darunavir/
ritonavir was safe and well tolerated in HIV-infected
patients; data suggest that no dose adjustment for daru-
navir/ritonavir is necessary.
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Table 1
DRV/r DRV/r + Echinacea GMR (95% CI) p
Cτ (ng/mL) 2.1 (1.6-2.7) 1.7 (1.4-2.2) 0.84 (0.59-1.19) 0.311
AUCτ (ng.h/mL) 46.2 (39.0-54.7) 41.6 (35.1-49.2) 0.90 (0.71-1.14) 0.374
Cmax (ng/mL) 6.4 (5.5-7.4) 6.2 (5.3-7.25) 0.98 (0.79-1.21) 0.810
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